Transcranial magnetic stimulation (TMS) is a neurotechnological practice developed by Anthony Barker and colleagues in Sheffield in 1985. It is among the most extensively validated non-invasive brain stimulation methods, with FDA clearance for treatment-resistant depression, OCD, and smoking cessation. It works through focal electromagnetic induction — brief magnetic pulses that depolarize neurons in targeted cortical regions.
The patient sits in a treatment chair while a clinician positions an electromagnetic coil against the scalp over a predetermined cortical target, most commonly the left dorsolateral prefrontal cortex. The device delivers patterned magnetic pulses calibrated to the individual's motor threshold. A standard session runs 19 to 37 minutes; theta burst protocols compress to 3 minutes.
Sessions run five days per week for four to six weeks. Patients feel a tapping sensation at the coil site, hear a loud clicking, and may notice brief facial muscle twitching. Common experiences include scalp discomfort, mild headache, and post-session fatigue. The procedure produces no sedation and no immediate alteration of consciousness — therapeutic effects emerge cumulatively over the treatment course.
The principal serious risk is seizure, with estimated incidence near 1 in 30,000 sessions in screened populations.[1] Personal history of epilepsy, intracranial metallic implants, and ferromagnetic devices near the head are absolute or relative contraindications. TMS is among the most extensively studied non-pharmacological interventions for treatment-resistant depression — meta-analyses of sham-controlled trials establish efficacy,[2] and FDA-cleared protocols are now reimbursed by major US insurers.
History & Tradition
TMS was developed by Anthony Barker, Reza Jalinous, and Ian Freeston at the Royal Hallamshire Hospital in Sheffield, with the first demonstration — a magnetic pulse over the motor cortex that produced a contralateral hand twitch — published in The Lancet in 1985.[3] The psychiatric application emerged from Mark George and colleagues at the NIH and MUSC, who published the first left prefrontal rTMS depression pilot in 1995.[4] The FDA cleared the first TMS device for treatment-resistant depression in October 2008,[5] with subsequent clearances for OCD (2018), smoking cessation (2020), an accelerated five-day protocol (2022), and adolescent depression (2023).
The Practice
Technique
Postural foundation
The patient sits upright in a treatment chair with adjustable head support to keep the coil in consistent contact with the scalp. No restraints, anesthesia, or sedation are used. Earplugs are worn throughout to protect against the loud click each magnetic discharge produces.
Core method
A clinician positions an electromagnetic coil — most commonly a figure-of-eight shape — against the scalp over a cortical target. At treatment initiation, the resting motor threshold (MT) is measured: the minimum stimulation intensity that produces a contralateral hand muscle twitch in half of trials. Therapeutic intensity is then set at 120% of the individual's MT. The standard protocol delivers 3,000 pulses per session over 37 minutes in trains of 40 pulses. The patient feels rhythmic tapping at the coil site and may notice facial or scalp muscle twitching from incidental peripheral nerve activation. The most common departure from protocol fidelity is coil drift — small displacements that shift the induced field off the intended cortical target without warning to the operator.
Progressive structure
The patient is passive throughout — there is no skill to acquire. A standard acute course runs 20 to 30 sessions over four to six weeks. Depression rating scales are re-administered every three to five sessions; non-responders at mid-course can have the protocol adjusted. Partial or full responders may be offered tapering continuation TMS, though evidence for maintenance is less robust than for the acute phase. Theta burst stimulation (iTBS) delivers the same therapeutic effect in 3 minutes per session rather than 37; the Stanford SAINT/SNT protocol further compresses a full course into five days using individualized fMRI-guided targeting.[6]
Setting & Preparation
TMS is delivered exclusively in clinical settings under physician supervision; the treatment room must contain the TMS device, a matched stimulating coil, EMG electrodes for motor threshold measurement, earplugs, and resuscitation equipment, with on-site personnel holding current basic life support certification.[1] A prescribing physician oversees indications, contraindication review, and motor threshold determination at initiation.
TMS is delivered only in clinical settings by trained operators under physician oversight. Harm reduction at the patient level centers on honest disclosure during the pre-treatment evaluation. Personal and family history of seizures, all intracranial implants, current medications — especially seizure-threshold-lowering agents — alcohol and substance use, recent sleep patterns, and pregnancy status all bear directly on safety planning.[1]
Before each session, patients should maintain regular sleep, avoid alcohol for at least 24 hours, and take prescribed medications as scheduled unless the prescribing physician has specified a hold. Earplugs must be confirmed in place before stimulation begins. Any new neurological symptoms — recent head injury, new headache pattern, unusual sensory experiences — should be reported to the treating clinician before the session, not only at intake.
Guidelines
- Do not proceed with TMS if there is personal history of epilepsy, unprovoked seizure, ferromagnetic intracranial implants, a cochlear implant, a deep brain stimulator, an aneurysm clip, or a cardiac pacemaker within the coil field — disclose all implants and prior neurological events to the prescribing physician.
- Disclose all current medications at intake and report any dose changes during the course, especially bupropion, tricyclic antidepressants, clozapine, stimulants, antiepileptics, and benzodiazepines.[1]
- Avoid alcohol for at least 24 hours before each session and maintain regular sleep — both acute intoxication and sleep deprivation elevate seizure risk.
- Confirm earplugs are in place at the start of every session — the coil click reaches roughly 120 dB and can cause permanent hearing threshold shifts.
- Stop and report to the operator immediately if any unusual neurological symptoms arise during a session — focal weakness, sudden severe headache, visual disturbance, or unprovoked anxiety; sessions can be paused or stopped at any time.
- For patients with bipolar disorder or personal or family history of mania, agree on a monitoring plan with the prescribing physician before starting and report mood elevation or reduced sleep need promptly.
- Confirm the treatment center maintains resuscitation equipment and personnel with current basic life support certification.[1]
Mechanism
TMS delivers brief magnetic pulses through the scalp that directly depolarize neurons in a focal cortical region; repeated sessions produce lasting changes in cortical excitability through mechanisms similar to synaptic strengthening and weakening,[7] and for depression protocols stimulating the left prefrontal cortex is thought to suppress overactive limbic circuitry through network connections.[8]
Subjective Effects
TMS does not alter consciousness during a session — the patient remains fully alert throughout. The dominant acute experience is physical: rhythmic tapping at the coil site, the clicking sound of each pulse attenuated by earplugs, and often brief facial or scalp muscle twitching. Mild headache and post-session fatigue are common and typically resolve within hours.[1] Therapeutic effects — mood improvement in depression — do not emerge during a single session but accumulate gradually over a full course, typically becoming noticeable between sessions 10 and 20.
▸▾Effect Grid
Clinician-administered magnetic stimulation to a cortical target.
Safety
Adverse Effects
Common, mild, and transient
Headache at or near the stimulation site is the most frequently reported adverse effect, occurring in approximately 5 to 20% of patients.[1] Scalp discomfort, coil-contact pain, and visible twitching of scalp or facial muscles during stimulation are common; they reflect incidental peripheral nerve and muscle activation and resolve within hours. Habituation across sessions reduces their frequency. Neck pain from head positioning, post-session fatigue, brief lightheadedness, and rare vasovagal syncope are also documented. The coil click reaches approximately 120 dB and can produce hearing threshold shifts without earplug protection.[1]
Seizure
Seizure is the most serious adverse event associated with TMS. Estimated incidence in screened populations is approximately 1 in 30,000 sessions, with per-patient risk below 1% in individuals without known seizure risk factors.[1] Patients with epilepsy carry substantially elevated risk — approximately 2.9% per patient. Risk-elevating factors include stimulation frequency above 10 Hz, intensity above 130% of motor threshold, reduced intertrain intervals, and concurrent seizure-threshold-lowering medications — bupropion, tricyclics, stimulants, clozapine — as well as recent alcohol use, sleep deprivation, and prior brain injury. All TMS-induced seizures in the published literature have been self-limited with no permanent neurological sequelae.
Mood switching
Treatment-emergent mania has been reported in patients with bipolar disorder and in those with personal or family history of mania. Current guidelines recommend heightened monitoring for manic symptoms during a TMS course in bipolar patients and shared decision-making about whether to proceed.[1]
No documented structural damage
No structural brain changes on MRI have been documented in humans undergoing clinical rTMS protocols. Animal histological changes have been reported only at parameters substantially exceeding clinical exposure.[1]
Contraindications
Absolute contraindications
Ferromagnetic or electronically active metallic implants within approximately 30 cm of the coil are an absolute contraindication. This includes cochlear implants, deep brain stimulators, vagal nerve stimulators, aneurysm clips, and cranial metal plates. Cardiac pacemakers and implantable cardioverter-defibrillators are contraindicated when the coil risks coupling to the device, with case review required.[1] Personal history of epilepsy or any unprovoked seizure is generally treated as an absolute contraindication for high-frequency rTMS.
Relative contraindications and elevated-risk populations
Family history of seizure, prior brain injury or stroke, intracranial lesion, and active substance use disorders involving stimulants or alcohol require pre-treatment risk assessment.[1] Concurrent use of bupropion, tricyclic antidepressants, clozapine, or stimulants is not an absolute contraindication but requires documented review of seizure-risk implications. Pregnancy is a relative contraindication for prefrontal stimulation; most clinics defer non-urgent treatment to the postpartum period. Bipolar disorder requires monitoring for manic switching.
Anatomical considerations
Recent neurosurgery, scalp wounds at the target site, and significant cortical lesions under the intended target are relative contraindications. Metallic dental work outside the immediate coil field is typically not a concern.
Substance Interactions
The primary interaction concern is pharmacologically mediated seizure-threshold reduction. Bupropion lowers seizure threshold in a dose-dependent manner — the most frequently cited interaction in TMS safety guidelines.[1] It is not an absolute contraindication but requires documented risk assessment; at higher doses, parameter adjustment is needed. Tricyclic antidepressants carry a similar dose-dependent reduction. Clozapine has a well-characterized seizure-threshold reduction and requires careful protocol planning. Stimulants — amphetamines and methylphenidate — elevate seizure risk and are assessed case by case.
Alcohol around the treatment window elevates seizure risk through intoxication, withdrawal rebound, and pharmacokinetic interactions with co-prescribed medications. Heavy regular use is a relative contraindication pending clinical risk review.[1] Acute discontinuation of anticonvulsants or benzodiazepines substantially raises seizure risk; any recent dose changes should be reviewed before each session.
A naturalistic cohort of 1,753 patients found that concomitant antidepressant use did not reduce clinical response and that no antidepressant class was associated with differential outcome.[9] SSRIs, SNRIs, and MAOIs have not shown major adverse interactions in published trials.[10]
TMS is under investigation for substance use disorders, with small-to-moderate craving-reduction effects reported for alcohol, nicotine, and cocaine.[11][12] No FDA clearance exists for any substance use indication; the interaction concerns above apply with particular force when depression TMS is pursued alongside active substance use.
Habituation
TMS carries no documented habituation, tolerance, or compulsive-use pattern. The procedure is administered exclusively in clinical settings; patients cannot self-administer it, and no recreational use pattern exists. No withdrawal syndrome has been characterized on discontinuation.
The relevant long-term question is durability of response rather than dependence. Most randomized trials follow patients only to the end of the acute course or to roughly six months; relapse rates over one to two years are not precisely characterized in controlled data.[13] Continuation TMS — tapering from weekly to monthly sessions over three to six months — is offered by some centers with evidence weaker than the acute phase. Patients who relapse after an initial successful course often respond to a repeat course, though this has not been studied with the rigor of first-course data.
If Distress Arises
Sessions can be paused or stopped at any time by the patient or the operator. The patient remains fully conscious and can communicate throughout. Mild scalp discomfort, tapping sensations, and facial twitching are expected and do not warrant stopping. Persistent or worsening headache, sudden severe pain at the coil site, lightheadedness, nausea, or new neurological symptoms — unilateral weakness, visual disturbance, slurred speech — are indications to stop and report immediately.
If a seizure occurs, the operator stops stimulation immediately, positions the patient safely, and follows standard seizure-response protocol. All TMS-induced seizures in the published literature have been self-limited and have not produced permanent neurological sequelae.[1] Resuscitation equipment and personnel with basic life support training are required on site for this contingency.
If a session is missed, resume the protocol without dose escalation — missed sessions do not require restarting the course. Patients who develop manic symptoms — elevated mood, decreased sleep need, racing thoughts, impulsive behavior — should contact the prescribing physician before the next session.
Recovery & Support
TMS does not produce dependence or withdrawal, so recovery in the substance-use sense does not apply. Post-course support focuses on relapse monitoring. Patients are typically followed with validated symptom scales (PHQ-9, HAMD-17, MADRS) at one, three, and six months post-course, and re-evaluated for a maintenance course or a repeat acute course at relapse.
For acute psychiatric emergencies during or after a TMS course — suicidal ideation, severe mood deterioration, or treatment-emergent mania — contact the prescribing physician, the treating center's on-call line, or emergency services. In the United States, the 988 Suicide and Crisis Lifeline is available 24/7 by call or text.
Non-response to an acute course does not preclude response to alternative protocols — iTBS if standard 10 Hz failed, or vice versa — or to individualized fMRI-guided targeting or other neuromodulation approaches. Non-response to TMS is not a marker of unusual treatment resistance.
Recovery resources, crisis lines, and support pathways → View all
Progression
TMS has no patient-side skill progression — the patient is passive during administration, and no published model of patient-acquired competence exists. A standard acute course consists of 20 to 30 sessions over four to six weeks,[10] with depression rating scales re-administered every three to five sessions and protocol adjustment available at mid-course for non-responders. Partial or full responders may be offered tapering continuation TMS, though evidence for maintenance is less robust than for the acute phase.[13]
Evidence Summary
Strong evidence. Multiple large sham-controlled RCTs, independent NIH-funded replications, and meta-analyses across hundreds of patients establish that left DLPFC rTMS produces significantly greater response and remission than sham in treatment-resistant major depression, with Level A evidence in IFCN guidelines across depression, neuropathic pain, and post-stroke rehabilitation.[13][2]
Limitations
Effect sizes are moderate and sham blinding is imperfect — patients can sometimes distinguish active from sham stimulation, inflating the placebo response.[2][14] Durability beyond the acute course is incompletely characterized, no pretreatment biomarker reliably predicts response, and for non-depression indications evidence ranges from FDA-cleared to early-validation supported only by small trials.[13]
references
- [1] ^abcdefghijklmnopRossi, S. and Antal, A. and Bestmann, S. and Bikson, M. and Brewer, C. and Brockmöller, J. and Carpenter, L.L. and Cincotta, M. and Chen, R. and Daskalakis, J.D. and et al. (IFCN Committee) (2021) Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines — Clinical Neurophysiology doi:10.1016/j.clinph.2020.10.003
- [2] ^abcBerlim, M.T. and Van den Eynde, F. and Tovar-Perdomo, S. and Daskalakis, Z.J. (2014) Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials — Psychological Medicine doi:10.1017/s0033291713001712
- [3] ^Barker, A.T. and Jalinous, R. and Freeston, I.L. (1985) Non-invasive magnetic stimulation of human motor cortex — The Lancet doi:10.1016/s0140-6736(85)92413-4
- [4] ^George, M.S. and Wassermann, E.M. and Williams, W.A. and Callahan, A. and Ketter, T.A. and Basser, P. and Hallett, M. and Post, R.M. (1995) Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression — NeuroReport doi:10.1097/00001756-199510020-00008
- [5]
- [6] ^Cole, E.J. and Phillips, A.L. and Bentzley, B.S. and Stimpson, K.H. and Nejad, R. and Barmak, F. and Veerapal, C. and Khan, N. and Cherian, K. and Felber, E. and Brown, R. and Keynan, J.N. and Pankow, H. and Bishop, J.H. and Hawkins, J. and Weyandt, S. and Azeez, A. and Gholmieh, M. and Coetzee, J.P. and Sudheimer, K.D. and Keller, J. and Raj, K.S. and Jo, B. and Espil, F.M. and Solvason, H.B. and Bhati, M.T. and O'Hara, R. and Williams, N.R. (2022) Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial — American Journal of Psychiatry doi:10.1176/appi.ajp.2021.20101429